Tekla Capital Management is a venture capital firm in Boston that focuses on securities of public and private healthcare companies. Founded 1986 in Boston, Massachusetts, United States, this venture capital invests in early stage ventures and late stage ventures. Its portfolio companies include VectivBio, Arkuda Therapeutics, Amphivena Therapeutics, Oculis, Milestone Pharmaceuticals, CuraSen Therapeutics, Galera Therapeutics, Atreca, Therachon, and Sutro Biopharma. As of February 2020, Tekla Capital Management has made 26 investments. Their most recent investment was on January 8, 2020, when VectivBio raised $35M. Tekla Capital Management has had 14 exits, the most notable of which include Atreca, CytomX Therapeutics, and Sutro Biopharma.